Life Sciences Tools and Services
Company Overview of MediBIC Group
MediBIC Group provides healthcare and drug development services. It provides genetic testing services with diagnostic tools to doctors; GLP-compliant gene profiling services to pharmaceutical companies; and sample banking and management services, as well as focuses on providing health care services to pets. The company is also involved in developing a cell culture system; selling consumables; promoting licensing activities for the pancreatic cancer drug Glufosfamide; the research and development of pharmaceuticals and diagnostic agents, etc.; and providing data analysis for preventive health care, as well as clinical trial services to cell therapy. MediBIC Group was founded in 2000 and is he...
Rohto Tokyo Building
Founded in 2000
Key Executives for MediBIC Group
President and Representative Director
Chief Operating Officer and Vice President
Executive Officer, General Manager of Administrative Division and Director
Chief Representative of Shanghai Office
Compensation as of Fiscal Year 2017.
MediBIC Group Key Developments
MediBIC Group To Be Delisted From Tokyo Stock Exchange
Sep 7 16
MediBIC Group will be delisted from Tokyo Stock Exchange, effective October 6, 2016. The delisting was due to the sales of a company is less than the required value.
MediBIC Group Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2016; Provides Earnings Guidance for the Six Months Ending June 2016 and Fiscal Ending December 2016
May 11 16
MediBIC Group reported consolidated earnings results for the first quarter ended March 31, 2016. The company reported net sales of ¥52 million, operating loss of ¥114 million, net loss attributable to owners of parent of ¥112 million or ¥3.81 per share against net sales of ¥35 million, operating loss of ¥113 million, net loss attributable to owners of parent of ¥145 million or ¥4.98 per share a year ago.
For the six months ending June 2016, the company expects net sales of ¥108 million, operating loss of ¥80 million, net loss attributable to owners of parent of ¥79 million or ¥2.72 per share.
For the fiscal ending December 2016, the company expects net sales of ¥364 million, operating income of ¥5 million, net income attributable to owners of parent of ¥3 million or ¥0.12 per share.
MediBIC Group to Report Q1, 2016 Results on May 11, 2016
Apr 26 16
MediBIC Group announced that they will report Q1, 2016 results on May 11, 2016
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries